Skip to content
    F-Prime Capital logo

    F-Prime Capital

    Cambridge, Massachusetts, United StatesFounded 1969

    F-Prime Capital (formerly Fidelity Biosciences) is the venture capital arm of Fidelity Investments/FMR LLC, investing in healthcare and technology companies. It was formed in 2015 when Fidelity Biosciences merged with Devonshire Investors' technology venture fund.

    Average disclosed round size is $51.6M (across 405 rounds with reported amounts).

    Find people at F-Prime Capital on Goldilocks AI

    Portfolio

    273

    Fund Size

    —

    Top Stage

    Series A

    Last 12 Mo

    25

    Team

    DJ

    David Jegen

    Partner

    GT

    Gaurav Tuli

    Partner

    JL

    Jon Lim

    Partner

    AA

    Abdul Abdirahman

    Principal

    EL

    Erica Lee

    Principal

    NA

    Nikhil Ananth

    Principal

    JN

    Jack Neureuter

    Investor

    KC

    Kevin Chu

    Healthcare Venture Capital

    AW

    Abby Wagner

    AP

    Alex Pasteur, PhD

    AG

    Allan Galper

    AM

    Allison MacLeod

    Portfolio Breakdown

    Stage Distribution

    Sector Distribution

    Investment Activity

    DealsAvg Round Size

    Portfolio

    452 investments
    CompanyRoundAmountDate
    Twin1 Ai logoTwin1 AiSeed$20MAug 2026
    Silicon Data logoSilicon DataSeries A$30.5MAug 2026
    Flourish logoFlourishSeries A$26MJul 2026
    Cyclops logoCyclopsSeries A$20MJul 2026
    Pie logoPieSeries A$19.5MJun 2026
    Immutrin logoImmutrinSeries A$87MMar 2026
    R1 Therapeutics logoR1 TherapeuticsSeries A$77.5MMar 2026
    Jump logoJumpSeries B$80MFeb 2026
    MMonarkSeries A$8.1MFeb 2026
    Jump logoJumpSeries B$80MFeb 2026
    MMonark MarketsStrategic$8.1MFeb 2026
    Tenpoint Therapeutics logoTenpoint TherapeuticsSeries B—Jan 2026
    Meld logoMeldSeries A$7MJan 2026
    Meld.io logoMeld.ioSeed$7MJan 2026
    Unbox logoUnboxSeries B$28MJan 2026
    VVenice AISeries A$65MJan 2026
    Enumerix logoEnumerixUnknown$26MJan 2026
    33F LabsSeed$4MJan 2026
    R1 Therapeutics logoR1 TherapeuticsSeries A$77.5MJan 2026
    Immutrin logoImmutrinSeries A$87MJan 2026
    Paradigm Health logoParadigm HealthSeries B$78MDec 2025
    Paradigm logoParadigmGrowth—Dec 2025
    Paradigm logoParadigmSeries B$78MDec 2025
    Wellbeam logoWellbeamSeries A$10MNov 2025
    T-Therapeutics logoT-TherapeuticsSeries A$91MNov 2025
    Page 1 of 19

    Top Co-Investors

    Last updated: 7 October 2026